Nova Eye Medical Limited Q2 2026 Sales & Trading Call: Record Quarter Highlights

Mark Flynn Investor Relations Good morning, everyone, and thank you for joining us today. This session will cover Nova Eye Medical's December 2025 quarterly sales results. And as we've stated in our ASX releases, it was a record quarter for the company, which we're very proud of. We run through our performance highlights, what drove the result and the priorities of the year ahead. As always, you're welcome to submit any questions. I have received many already. Tom and I will look to address at the end of the session. But now I'll just pass straight over to Tom Spurling, our Managing Director, and he will take you through our potential sales performance and also the outlook for this year. So over to you, Tom. Thomas Spurling MD & Executive Director Thanks, Mark. So welcome, everybody. Thanks for tuning in. 90 registrations as of this morning, which is wonderful. It's -- our mission is to -- well, what we're aiming with this session is to keep our shareholders right up to date with what's going on because we are a fast-growing company, and the news is good. So we'll get right into it. Here's our disclaimer. Just some of you would have seen this slide before, I don't want to underestimate the importance of the market we're in. Interventional glaucoma. The idea is that the active engagement or surgical engagement to change the disease trajectory earlier in the disease state and trying to get people off drops, which generally result in a poor quality of life outcomes. The data we have shows pharma spend is falling slightly. It's a big market, but it's falling slightly. And surgical devices are growing.